Clinical Research Directory
Browse clinical research sites, groups, and studies.
Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
Sponsor: China National Center for Cardiovascular Diseases
Summary
The goal of this clinical trial is to learn if calcium-phosphorus regulation therapy can slow the progression of heart valve calcification in patients with degenerative heart valve disease and chronic kidney disease (CKD). The main questions it aims to answer are: * Does Sevelamer lower the progression of heart valve calcification compared to calcium carbonate over 12 months? * What are the impacts of calcium-phosphorus regulation therapy on major cardiovascular events such as heart failure, cardiovascular death, and the need for valve surgery? Researchers will compare Sevelamer to calcium carbonate to see if Sevelamer is more effective in reducing heart valve calcification. Participants will: * Take Sevelamer or calcium carbonate daily for 12 months. * Undergo echocardiography and CT scans at baseline and after 12 months to assess heart valve calcification. * Attend follow-up visits at 3, 6, 9, and 12 months to monitor blood tests and adjust treatment as needed.
Official title: Clinical Study on the Influence of Calcium and Phosphorus Regulation Therapy on Valvular Heart Disease.
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
196
Start Date
2024-03-01
Completion Date
2025-12
Last Updated
2024-10-28
Healthy Volunteers
No
Conditions
Interventions
Sevelamer
Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
Calcium carbonate
Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
Locations (1)
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science
Beijing, Beijing Municipality, China